Advertisement

Table of Contents

Editorial

J Mendelsohn

Clin Cancer Res July 1 1995 1 (7) 675-675;
Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic.

W Ki Hong, S M Lippman, W N Hittelman and R Lotan

Clin Cancer Res July 1 1995 1 (7) 677-686;
Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.

J P Packenham, J A Taylor, C M White, C H Anna, J C Barrett and T R Devereux

Clin Cancer Res July 1 1995 1 (7) 687-690;
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.

K Dhingra, D Frye, R A Newman, R Walters, R Theriault, G Fraschini, T Smith, A Buzdar and G N Hortobagyi

Clin Cancer Res July 1 1995 1 (7) 691-697;
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).

M E Costanza, D Berry, I C Henderson, M J Ratain, K Wu, C Shapiro, D Duggan, J Kalra, I Berkowitz and A P Lyss

Clin Cancer Res July 1 1995 1 (7) 699-704;
Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.

A Mittelman, G Z Chen, G Y Wong, C Liu, S Hirai and S Ferrone

Clin Cancer Res July 1 1995 1 (7) 705-713;
Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.

R L Basser, L B To, C G Begley, C A Juttner, D W Maher, J Szer, J Cebon, J P Collins, I Russell and I Olver

Clin Cancer Res July 1 1995 1 (7) 715-721;
Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death.

J A Houghton, D M Tillman and F G Harwood

Clin Cancer Res July 1 1995 1 (7) 723-730;
Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.

L G Remsen, C I McCormick, G Sexton, H D Pearse, R Garcia and E A Neuwelt

Clin Cancer Res July 1 1995 1 (7) 731-739;
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.

C Thomssen, M Schmitt, L Goretzki, P Oppelt, L Pache, P Dettmar, F Jänicke and H Graeff

Clin Cancer Res July 1 1995 1 (7) 741-746;
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.

A Waghray and M M Webber

Clin Cancer Res July 1 1995 1 (7) 747-753;
Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.

M M Webber and A Waghray

Clin Cancer Res July 1 1995 1 (7) 755-761;
Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.

J C Law, T L Whiteside, S M Gollin, J Weissfeld, L El-Ashmawy, S Srivastava, R J Landreneau, J T Johnson and R E Ferrell

Clin Cancer Res July 1 1995 1 (7) 763-768;
p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.

I Shibagaki, H Tanaka, Y Shimada, T Wagata, M Ikenaga, M Imamura and K Ishizaki

Clin Cancer Res July 1 1995 1 (7) 769-773;
Absence of p53 autoantibodies in sera from glioma patients.

N G Rainov, K U Dobberstein, M Fittkau, H Bahn, H J Holzhausen, L Gantchev and W Burkert

Clin Cancer Res July 1 1995 1 (7) 775-781;